Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS)
Myelodysplastic Syndrome (MDS)
About this trial
This is an interventional treatment trial for Myelodysplastic Syndrome (MDS)
Eligibility Criteria
Inclusion Criteria: Histologically confirmed diagnosis of MDS Documented significant cytopenia for at least 2 months Adequate liver and kidney function Ineligible for stem cell bone marrow transplantation At least 18 years of age Discontinuation of growth factors (e.g., G-CSF) within 3 weeks of study entry Exclusion Criteria: Prior bone marrow transplant Failure to recover from any prior surgery or any major surgery within 4 weeks of study entry Pregnant or lactating women Other investigational drugs within 14 days of study entry Chemotherapy, radiotherapy or immunotherapy within 14 days of study entry
Sites / Locations
- Loyola University Chicago-Cardinal Bernardin Cancer Center
- Loyola University Medical Center
- University of Massachusetts (UMass) Memorial Medical Center
Arms of the Study
Arm 1
Experimental
1
Dose Escalation Study of TLK199 Tablets From 200 mg Per day To 6000 mg Per Day